Corbus Pharmaceuticals presented Phase 1 data on CRB-701 at ASCO GU, showing safety, tolerability, and responses across multiple tumor types.

The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

Anomaly detection can be powerful in spotting cyber incidents, but experts say CISOs should balance traditional ...

A one-time injection of Lumevoq demonstrated sustained visual acuity improvements with a favorable safety profile at 5 years ...

Allurion’s CEO confirmed to Medical Device Network that the company has changed advertising, patient follow-up, and physician ...

Despite severe risks and without a crime committed, a Minnesota judge authorized doctors to forcibly administer ...

Most patients with moderately to severely active Crohn’s disease who achieved endoscopic response and remission after 52 ...

A network meta-analysis reveals age-dependent variations in efficacy of popular diabetes drugs, with SGLT2 inhibitors showing ...

A spin off from the Family Connector project has seen a number of schools create ‘Safe Spaces’ for children in their buildings.

Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within o ...

First chikungunya vaccine approved for persons as young as 12 years old, addressing an unmet need for chikungunya prevention for younger travelers.On track for commercial launch in the U.S. in the ...

Findings also suggested that an up-front dose reduction of enfortumab vedotin may benefit older patients with urothelial carcinoma.